Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer.

LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS.

Cancer Res. 2013 Apr 1;73(7):2070-81. doi: 10.1158/0008-5472.CAN-12-3526. Epub 2013 Feb 11.

2.

Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy.

Li D, Liu S, Shan H, Conti P, Li Z.

Theranostics. 2013 Jun 29;3(7):507-15. doi: 10.7150/thno.5557. Print 2013. Review.

3.

Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes.

Kriegbaum MC, Persson M, Haldager L, Alpízar-Alpízar W, Jacobsen B, Gårdsvoll H, Kjær A, Ploug M.

Curr Drug Targets. 2011 Nov;12(12):1711-28. Review.

PMID:
21707479
4.

Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.

Magdolen V, Krüger A, Sato S, Nagel J, Sperl S, Reuning U, Rettenberger P, Magdolen U, Schmitt M.

Recent Results Cancer Res. 2003;162:43-63. Review.

PMID:
12790320
5.

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.

Reuning U, Sperl S, Kopitz C, Kessler H, Krüger A, Schmitt M, Magdolen V.

Curr Pharm Des. 2003;9(19):1529-43. Review.

PMID:
12871066
6.

uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.

Lund IK, Illemann M, Thurison T, Christensen IJ, Høyer-Hansen G.

Curr Drug Targets. 2011 Nov;12(12):1744-60. Review.

PMID:
21707477
7.

Role of urokinase receptor in tumor progression and development.

Noh H, Hong S, Huang S.

Theranostics. 2013 Jun 25;3(7):487-95. doi: 10.7150/thno.4218. Print 2013. Review.

8.
9.

Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.

Miller-Kleinhenz JM, Bozeman EN, Yang L.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Nov-Dec;7(6):797-816. doi: 10.1002/wnan.1343. Epub 2015 May 12. Review.

10.

Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET.

Skovgaard D, Persson M, Kjaer A.

PET Clin. 2017 Apr;12(2):243-255. doi: 10.1016/j.cpet.2016.12.005. Epub 2017 Jan 31. Review.

PMID:
28267457
11.

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.

Indira Chandran V, Eppenberger-Castori S, Venkatesh T, Vine KL, Ranson M.

Oncoscience. 2015 Mar 23;2(3):207-24. eCollection 2015. Review.

12.

PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives.

Skovgaard D, Persson M, Kjaer A.

Clin Transl Imaging. 2016;4(6):457-465. doi: 10.1007/s40336-016-0197-4. Epub 2016 Jul 4. Review.

13.

Organization, evolution and functions of the human and mouse Ly6/uPAR family genes.

Loughner CL, Bruford EA, McAndrews MS, Delp EE, Swamynathan S, Swamynathan SK.

Hum Genomics. 2016 Apr 21;10:10. doi: 10.1186/s40246-016-0074-2. Review.

Supplemental Content

Support Center